{"id":"9bd4a39d-79ad-5713-868d-f2bacedf7c01","stable_key":"6b15b2de-9ce9-5b6f-ab8b-3c7dbb4c15c7:stevia-reba-ogtt-null","predicate":"did_not_reduce","statement":"In 30 adults with type 2 diabetes, 3 g oral rebaudioside A did not reduce two-hour OGTT glucose AUC versus placebo at the planned metabolite-peak time; insulin and C-peptide excursions were also comparable.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"fc70c22e-a8dc-5b51-8fe2-793298dbf7b5","mechanism_event_label":"Measurable circulating metabolites did not guarantee a glucose-lowering response.","subject":{"id":"16a5658c-2844-5742-9d3b-8882e5414eb6","slug":"rebaudioside-a","display_name":"Rebaudioside A","entity_type_key":"small_molecule"},"object":{"id":"6da73cd9-46fe-5fa3-b55f-a9f40827b0ef","slug":"human-reba-ogtt-glucose-auc","display_name":"Human OGTT glucose AUC after rebaudioside A","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"fc70c22e-a8dc-5b51-8fe2-793298dbf7b5","stable_key":"6b15b2de-9ce9-5b6f-ab8b-3c7dbb4c15c7:stevia-reba-ogtt-null-event","event_type":"observed_relationship","label":"Measurable circulating metabolites did not guarantee a glucose-lowering response.","description":"In 30 adults with type 2 diabetes, 3 g oral rebaudioside A did not reduce two-hour OGTT glucose AUC versus placebo at the planned metabolite-peak time; insulin and C-peptide excursions were also comparable.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"16a5658c-2844-5742-9d3b-8882e5414eb6","slug":"rebaudioside-a","display_name":"Rebaudioside A","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"6da73cd9-46fe-5fa3-b55f-a9f40827b0ef","slug":"human-reba-ogtt-glucose-auc","display_name":"Human OGTT glucose AUC after rebaudioside A","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"c78086c3-7657-589b-b353-1691df2d9f8f","slug":"stevia","display_name":"Stevia","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"8ba32fe6-183f-5cd5-b386-02e6440e78a0","slug":"steviol","display_name":"Steviol","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"f008b74d-164b-5663-a72e-04a48fe7a8fb","slug":"steviol-glucuronide","display_name":"Steviol glucuronide","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""},{"entity":{"id":"8ae7848b-f172-5e09-8acf-5ca914907b0b","slug":"glucose","display_name":"D-glucose","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":5,"notes":""},{"entity":{"id":"d7ab69c0-cd7d-587c-b315-47af56493182","slug":"insulin","display_name":"Insulin","entity_type_key":"protein"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":6,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomized open-label crossover; OGTT 19 hours after dosing.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Different molecule and test timing from the stevioside meal trial; not an automatic contradiction.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Stevia collection; species, compartment, exposure, co-substrates and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"stevia","display_name":"Stevia","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Measurable circulating metabolites did not guarantee a glucose-lowering response.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Pharmacokinetics of Oral Rebaudioside A in Patients with Type 2 Diabetes Mellitus and Its Effects on Glucose Homeostasis: A Placebo-Controlled Crossover Trial. · 2022 · https://pubmed.ncbi.nlm.nih.gov/36057030/ · DOI 10.1007/s13318-022-00792-7","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"9417d064-e0ce-5efa-a39c-2b94cf7c5ae1","evidence_kind":"source_excerpt","locator":"Lines 370-376","start_line":370,"end_line":376,"excerpt":"## stevia-reba-ogtt-null\nMeasurable circulating metabolites did not guarantee a glucose-lowering response.\nIn 30 adults with type 2 diabetes, 3 g oral rebaudioside A did not reduce two-hour OGTT glucose AUC versus placebo at the planned metabolite-peak time; insulin and C-peptide excursions were also comparable.\nModel: Randomized open-label crossover; OGTT 19 hours after dosing.\nLimitations: Different molecule and test timing from the stevioside meal trial; not an automatic contradiction.\nEvidence access: Primary abstract\nPharmacokinetics of Oral Rebaudioside A in Patients with Type 2 Diabetes Mellitus and Its Effects on Glucose Homeostasis: A Placebo-Controlled Crossover Trial. · 2022 · https://pubmed.ncbi.nlm.nih.gov/36057030/ · DOI 10.1007/s13318-022-00792-7","model_system":"Randomized open-label crossover; OGTT 19 hours after dosing.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"295304c9-609c-5b05-a18f-a00ab7b965ed","stable_key":"import-6b15b2de-9ce9-5b6f-ab8b-3c7dbb4c15c7","title":"Stevia: glycoside metabolism, taste, ion channels and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"a36a82c2f8a0a971ea43e9e742db65f45848d13ab77310c0dd6b5cd55e31fc16","revision_id":"ea0355af-a926-511a-a7f2-1750baa95a8d","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}